BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Al Ghazal P, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, Roth H, Rabe E, Karrer S, Renner R. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136. [PMID: 24010984 DOI: 10.1186/1750-1172-8-136] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Cosgarea R, Senilă SC, Badea R, Ungureanu L. Pyoderma gangrenosum with spleen involvement. Review of the literature and case report. J Dermatol Case Rep 2016;10:26-31. [PMID: 27900062 DOI: 10.3315/jdcr.2016.1230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gupta AS, Ortega-Loayza AG. Ocular pyoderma gangrenosum: A systematic review. J Am Acad Dermatol 2017;76:512-8. [PMID: 27836332 DOI: 10.1016/j.jaad.2016.08.049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
3 Körber A, Jockenhöfer F, Sondermann W, Stoffels-Weindorf M, Dissemond J. [First manifestation of leg ulcers : Analysis of data from 1000 patients]. Hautarzt 2017;68:483-91. [PMID: 28280910 DOI: 10.1007/s00105-017-3950-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Isoherranen K, O'brien JJ, Barker J, Dissemond J, Hafner J, Jemec GBE, Kamarachev J, Läuchli S, Montero EC, Nobbe S, Sunderkötter C, Velasco ML. Atypical wounds. Best clinical practice and challenges. J Wound Care 2019;28:S1-S92. [DOI: 10.12968/jowc.2019.28.sup6.s1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
5 Baliu-piqué C, Mascaró JM. Multifocal and refractory pyoderma gangrenosum: Possible role of cocaine abuse. Australas J Dermatol 2017;58:e83-6. [DOI: 10.1111/ajd.12498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges 2017;15:34-40. [PMID: 28140549 DOI: 10.1111/ddg.13173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr 2014;164:263-73. [DOI: 10.1007/s10354-014-0285-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
8 Herberger K, Dissemond J, Brüggestrat S, Sorbe C, Augustin M. Biologics and immunoglobulins in the treatment of pyoderma gangrenosum - analysis of 52 patients. J Dtsch Dermatol Ges 2019;17:32-41. [PMID: 30592563 DOI: 10.1111/ddg.13741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
9 Herberger K, Dissemond J, Brüggestrat S, Sorbe C, Augustin M. Biologika und Immunglobuline für die Therapie des Pyoderma gangraenosum - Analyse von 52 Patienten. J Dtsch Dermatol Ges 2019;17:32-42. [PMID: 30615279 DOI: 10.1111/ddg.13741_g] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Wolska K, Michalska-Jakubus M, Pucuła J, Chodorowska G, Dzida G, Mosiewicz J, Prystupa A, Podhorecka M, Krasowska D. Bullous pyoderma gangrenosum associated with pancytopenia of unknown origin. Postepy Dermatol Alergol 2014;31:272-6. [PMID: 25254015 DOI: 10.5114/pdia.2014.40980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Aktaş Karabay E, Aksu Cerman A, Kıvanc Altunay İ, Yalçın Ö. Bullous Pyoderma Gangrenosum With Subungual Involvement Associated With Ulcerative Colitis. Am J Dermatopathol 2017;39:476-8. [PMID: 27893467 DOI: 10.1097/DAD.0000000000000801] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Cosgarea I, Lovric Z, Körber A, Dissemond J. Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma. Int Wound J 2016;13:1041-2. [PMID: 25294697 DOI: 10.1111/iwj.12377] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
13 Dissemond J, Erfurt-Berge C, Goerge T, Kröger K, Funke-Lorenz C, Reich-Schupke S. Systemic therapies for leg ulcers. J Dtsch Dermatol Ges 2018;16:873-90. [PMID: 29989361 DOI: 10.1111/ddg.13586] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
14 Buhalog B, Eastman K, McDonald R. Recalcitrant pyoderma gangrenosum treated with parenteral iron sucrose therapy. JAAD Case Rep 2015;1:54-5. [PMID: 27051682 DOI: 10.1016/j.jdcr.2014.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Maverakis E, Marzano AV, Le ST, Callen JP, Brüggen M, Guenova E, Dissemond J, Shinkai K, Langan SM. Pyoderma gangrenosum. Nat Rev Dis Primers 2020;6. [DOI: 10.1038/s41572-020-0213-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
16 Meier B, Maul J, French LE. Pyoderma gangraenosum und Sweet-Syndrom: Hautmanifestationen autoinflammatorischer Erkrankungen. Hautarzt 2016;67:934-9. [DOI: 10.1007/s00105-016-3888-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Herberger K. [Pyoderma gangrenosum]. Hautarzt 2016;67:753-63. [PMID: 27492434 DOI: 10.1007/s00105-016-3847-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
18 Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. Int Wound J 2019;16:511-21. [PMID: 30604927 DOI: 10.1111/iwj.13067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
19 Al Ghazal P, Dissemond J. Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2015;13:317-24. [DOI: 10.1111/ddg.12585] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
20 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. World J Rheumatol 2015; 5(2): 101-107 [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Adışen E, Erduran F, Gürer MA. Pyoderma Gangrenosum: A Report of 27 Patients. Int J Low Extrem Wounds 2016;15:148-54. [PMID: 27009790 DOI: 10.1177/1534734616639172] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
22 Montagnon CM, Fracica EA, Patel AA, Camilleri MJ, Murad MH, Dingli D, Wetter DA, Tolkachjov SN. Pyoderma gangrenosum in hematologic malignancies: A systematic review. J Am Acad Dermatol 2020;82:1346-59. [PMID: 31560977 DOI: 10.1016/j.jaad.2019.09.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
23 Croitoru D, Naderi-Azad S, Sachdeva M, Piguet V, Alavi A. A Wound Care Specialist's Approach to Pyoderma Gangrenosum. Adv Wound Care (New Rochelle) 2020;9:686-94. [PMID: 32320358 DOI: 10.1089/wound.2020.1168] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, Lockwood SJ, James WD, Micheletti RG, Rosenbach M, Mostaghimi A. The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. JAMA Dermatol. 2018;154:409-413. [PMID: 29450453 DOI: 10.1001/jamadermatol.2017.5978] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]
25 Ighani A, Al‐mutairi D, Rahmani A, Weizman A, Piguet V, Alavi A. Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. Br J Dermatol 2019;180:672-3. [DOI: 10.1111/bjd.17347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Eisendle K, Thuile T, Deluca J, Pichler M. Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases. Adv Wound Care (New Rochelle) 2020;9:405-25. [PMID: 32320362 DOI: 10.1089/wound.2020.1160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
27 Pahnke F, Elsner P, Tittelbach J. [Rare cause of eruptively occurring ulcerating abscesses : Intralesional and perilesional postsurgical pathergy phenomenon in a misdiagnosed case]. Chirurg 2020;91:1062-5. [PMID: 32514943 DOI: 10.1007/s00104-020-01215-6] [Reference Citation Analysis]
28 Coster A, Dargent J, de Visscher N, Levecque P, Roquet-gravy P. Pyoderma gangrenosum avec anticorps anti-cytoplasme des neutrophiles de type anti-protéinase 3 (PR3-ANCA) induits par le propylthiouracile. Annales de Dermatologie et de Vénéréologie 2017;144:368-73. [DOI: 10.1016/j.annder.2017.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Arslan F, Karagoz E, Yılmaz M, Mert A. Visual vignette. Endocr Pract 2015;21:299. [PMID: 25536974 DOI: 10.4158/EP14507.VV] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Gupta AS, Ortega-loayza AG. Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. Ann Hematol 2019;98:2247-8. [DOI: 10.1007/s00277-019-03732-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
31 Afifi L, Sanchez IM, Wallace MM, Braswell SF, Ortega-loayza AG, Shinkai K. Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. Journal of the American Academy of Dermatology 2018;78:1195-1204.e1. [DOI: 10.1016/j.jaad.2017.12.049] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 8.7] [Reference Citation Analysis]
32 Inoue S, Furuta JI, Fujisawa Y, Onizawa S, Ito S, Sakiyama M, Kobayashi K, Kanou T, Iijima S, Ohi T, Okubo C, Moriyama Y, Okiyama N, Fujimoto M. Pyoderma gangrenosum and underlying diseases in Japanese patients: A regional long-term study. J Dermatol 2017;44:1281-4. [PMID: 28635156 DOI: 10.1111/1346-8138.13937] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
33 Garcovich S, De Simone C, Berti E, Marzano AV. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017;10:1119-28. [PMID: 28715916 DOI: 10.1080/17512433.2017.1356719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
34 Tolkachjov SN, Fahy AS, Cerci FB, Wetter DA, Cha SS, Camilleri MJ. Postoperative Pyoderma Gangrenosum: A Clinical Review of Published Cases. Mayo Clin Proc 2016;91:1267-79. [PMID: 27489052 DOI: 10.1016/j.mayocp.2016.05.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
35 Tolkachjov SN, Fahy AS, Wetter DA, Brough KR, Bridges AG, Davis MD, el-Azhary RA, Mcevoy MT, Camilleri MJ. Postoperative pyoderma gangrenosum (PG): The Mayo Clinic experience of 20 years from 1994 through 2014. Journal of the American Academy of Dermatology 2015;73:615-22. [DOI: 10.1016/j.jaad.2015.06.054] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
36 Dissemond J, Erfurt-Berge C, Goerge T, Kröger K, Funke-Lorenz C, Reich-Schupke S. Systemische Therapien des Ulcus cruris. J Dtsch Dermatol Ges 2018;16:873-92. [PMID: 29989366 DOI: 10.1111/ddg.13586_g] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Yamamoto T. Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey. J Dermatol 2018;46:e145-6. [DOI: 10.1111/1346-8138.14658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
38 Clark LG, Tolkachjov SN, Bridges AG, Camilleri MJ. Pyostomatitis vegetans (PSV)-pyodermatitis vegetans (PDV): A clinicopathologic study of 7 cases at a tertiary referral center. Journal of the American Academy of Dermatology 2016;75:578-84. [DOI: 10.1016/j.jaad.2016.03.047] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
39 Jockenhöfer F, Herberger K, Schaller J, Hohaus KC, Stoffels-Weindorf M, Ghazal PA, Augustin M, Dissemond J. Trizentrische Analyse von Kofaktoren und Komorbidität des Pyoderma gangraenosum. J Dtsch Dermatol Ges 2016;14:1023-31. [PMID: 27767262 DOI: 10.1111/ddg.12791_g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
40 Jiang YY, Li J, Li Y, Wang Q, Liu S, Fang K, Qian JM, Jin HZ. Comparison of Clinical Features between Pyoderma Gangrenosum Concomitant by Inflammatory Bowel Disease and Idiopathic Pyoderma Gangrenosum. Chin Med J (Engl) 2017;130:2674-9. [PMID: 29133754 DOI: 10.4103/0366-6999.218004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
41 Jockenhöfer F, Klode J, Kröger K, Roesch A, Al Ghazal P, Dissemond J. Patients with pyoderma gangrenosum - analyses of the German DRG data from 2012. Int Wound J 2016;13:951-6. [PMID: 26250591 DOI: 10.1111/iwj.12463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
42 Wollina U. Pyoderma gangrenosum—a systemic disease? Clinics in Dermatology 2015;33:527-30. [DOI: 10.1016/j.clindermatol.2015.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
43 Soro-García J, García-Fontán EM, Carrasco-Rodríguez R, Blanco-Ramos M, Cañizares-Carretero MA. Atypical pyoderma gangrenosum simulating pectoral abscess managed using negative pressure wound therapy. Rev Port Pneumol (2006) 2017;23:306-7. [PMID: 28676413 DOI: 10.1016/j.rppnen.2017.05.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Xu A, Balgobind A, Strunk A, Garg A, Alloo A. Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis. J Am Acad Dermatol 2020;83:425-9. [PMID: 31400451 DOI: 10.1016/j.jaad.2019.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
45 Bingoel AS, Krezdorn N, Kaltenborn A, Dastagir K, Jokuszies A, Mett TR, Vogt PM. The surgical approach to Pyoderma gangrenosum: A retrospective monocenter study. Wound Repair Regen 2021;29:478-85. [PMID: 33835625 DOI: 10.1111/wrr.12918] [Reference Citation Analysis]
46 Pearson WA, Prentice DA, Sinclair DL, Lim LY, Carville KJ. A novel topical therapy for resistant and early peristomal pyoderma gangrenosum. Int Wound J 2019;16:1136-43. [PMID: 31298491 DOI: 10.1111/iwj.13164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
47 Eddou H, Ennouhi A, Sina M, Zinebi A, El Benaye J, Moudden M, Doghmi K, Malfuson J, Mikdame M, El Baaj M. Pyoderma gangrenosum après allogreffe de cellules souches hématopoïétiques. Annales de Dermatologie et de Vénéréologie 2018;145:445-50. [DOI: 10.1016/j.annder.2018.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Monari P, Moro R, Motolese A, Misciali C, Baraldi C, Fanti PA, Caccavale S, Puviani M, Olezzi D, Zampieri P, Trevisan G, Nan K, Fiorentini C, Pellacani G, Gualdi G. Epidemiology of pyoderma gangrenosum: Results from an Italian prospective multicentre study. Int Wound J 2018;15:875-9. [PMID: 29877043 DOI: 10.1111/iwj.12939] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
49 Ruffer N, Krusche M, Holzer MT, Hagel C, Kötter I. [Differential diagnosis of a vasculitic syndrome of the lower limb]. Z Rheumatol 2021. [PMID: 34241690 DOI: 10.1007/s00393-021-01044-w] [Reference Citation Analysis]
50 Gillard M, Anuset D, Maillard H, Senet P, Cuny JF, Mahe E, Sin C, Dessiner F, Goujon E, Journet-tollhupp J, Debure C, Dabouz F, Develter T, Bernard P, Lok C, Modiano P; Members of the Groupe d'Angiodermatologie de la SFD (the Angiodermatological Group of the French Society of Dermatology). Comorbidities of pyoderma gangrenosum: a retrospective multicentric analysis of 126 patients. Br J Dermatol 2018;179:218-9. [DOI: 10.1111/bjd.16463] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
51 Kridin K, Cohen AD, Amber KT. Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis. Am J Clin Dermatol 2018;19:479-87. [PMID: 29721816 DOI: 10.1007/s40257-018-0356-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 9.7] [Reference Citation Analysis]
52 Kridin K, Solomon A, Britva RL, Bitan DT, Cohen AD. Chronic renal comorbidities in pyoderma gangrenosum: a retrospective cohort study. Immunol Res 2021;69:249-54. [PMID: 33890227 DOI: 10.1007/s12026-021-09187-3] [Reference Citation Analysis]
53 Platzer K, Kostner L, Vujic I, Monshi B, Richter L, Rappersberger K, Posch C. Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients – a retrospective, single institution observation. J Eur Acad Dermatol Venereol 2019;33. [DOI: 10.1111/jdv.15803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Saffie MG, Shroff A. A Case of Pyoderma Gangrenosum Misdiagnosed as Necrotizing Infection: A Potential Diagnostic Catastrophe. Case Rep Infect Dis 2018;2018:8907542. [PMID: 29854503 DOI: 10.1155/2018/8907542] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Bucchia M, Barbarot S, Reumaux H, Piram M, Mahe E, Mallet S, Balguerie X, Phan A, Lacour JP, Decramer S, Hatchuel Y, Jean S, Begon E, Joubert A, Merlin E, Wallach D, Meinzer U, Bourrat E; Groupe de recherche de la Société Française de Dermatologie Pédiatrique; Société Francophone pour la rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP). Age-specific characteristics of neutrophilic dermatoses and neutrophilic diseases in children. J Eur Acad Dermatol Venereol 2019;33:2179-87. [PMID: 31166045 DOI: 10.1111/jdv.15730] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Jockenhöfer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019;180:615-20. [PMID: 29388188 DOI: 10.1111/bjd.16401] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
57 Jockenhöfer F, Herberger K, Schaller J, Hohaus KC, Stoffels-Weindorf M, Ghazal PA, Augustin M, Dissemond J. Tricenter analysis of cofactors and comorbidity in patients with pyoderma gangrenosum. J Dtsch Dermatol Ges 2016;14:1023-30. [PMID: 27767288 DOI: 10.1111/ddg.12791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
58 Szalat R, Monsel G, Le Goff W, Battistella M, Bengouffa D, Schlageter M, Bouaziz J, Arnulf B, Vignon M, Lesnik P, Saussine A, Malphettes M, Lazareth A, Vignon-pennamen M, Bagot M, Brouet J, Fermand J, Rybojad M, Asli B. The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: Association with IgA isotype and inflammatory profile. Journal of the American Academy of Dermatology 2015;73:809-20. [DOI: 10.1016/j.jaad.2015.07.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
59 王超鹏, 刘素琴. 溃疡性结肠炎并发坏疽性脓皮病的诊治护理1例. 世界华人消化杂志 2015; 23(8): 1374-1378 [DOI: 10.11569/wcjd.v23.i8.1374] [Reference Citation Analysis]
60 Wollina U. Emerging treatments for pyoderma gangrenosum. Expert Opinion on Orphan Drugs 2017;5:827-32. [DOI: 10.1080/21678707.2017.1375404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Fongue J, Brajon D, Visée C, Combes E, Andrac-Meyer L, Berbis P. [Pyoderma gangrenosum revealing colonic diverticulitis: Two cases]. Ann Dermatol Venereol 2015;142:664-9. [PMID: 26372545 DOI: 10.1016/j.annder.2015.07.013] [Reference Citation Analysis]
62 Vallini V, Andreini R, Bonadio A. Pyoderma Gangrenosum: A Current Problem as Much as an Unknown One. The International Journal of Lower Extremity Wounds 2017;16:191-201. [DOI: 10.1177/1534734617710980] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]